- What sets clinical trial protocol translation apart
- Regulatory requirements for submission in Europe and Portuguese-speaking markets
- Quality and certification: what regulators expect
- Managing protocol amendments and version control
- Clinical trial protocol translation with M21Global
- Frequently Asked Questions
Submitting a clinical trial protocol to a regulatory authority — whether the EMA, INFARMED in Portugal, the MHRA in the UK, or ANVISA in Brazil — requires documentation translated with both technical precision and regulatory awareness. A terminological error in endpoint definitions, inclusion criteria, or dosing instructions can delay approval or trigger a formal request for clarification that sets the timeline back by weeks.
What sets clinical trial protocol translation apart
Clinical trial protocols are highly structured regulatory documents. They follow defined templates — typically aligned with ICH E6(R2) Good Clinical Practice guidelines — and contain densely specialised terminology across sections such as:
- Primary and secondary endpoints
- Inclusion and exclusion criteria
- Randomisation and blinding procedures
- Adverse events and serious adverse reactions (SAEs/SARs)
- Dosing schedules and routes of administration
- Statistical analysis plan and sample size calculations
The translation must preserve not only the clinical meaning but also the formal document structure. Regulators review translated versions for consistency with the source, and any divergence — even a subtle one in safety terminology — is grounds for a query.
Regulatory requirements for submission in Europe and Portuguese-speaking markets
Under EU Regulation No 536/2014 on clinical trials of medicinal products for human use, certain documents must be available in the language of the Member State where the trial is conducted. Documents intended for participants — in particular the Informed Consent Form — must be translated into the local language regardless of the language in which the full protocol is filed via the CTIS portal.
Documents most commonly subject to translation in regulatory submissions include:
- Full protocol and all subsequent amendments
- Investigator's Brochure (IB)
- Informed Consent Form (ICF)
- Summaries of pre-clinical and clinical studies
- Investigational Medicinal Product (IMP) dossiers and labels
- Periodic safety reports (DSUR, SUSAR narratives)
In Portugal, INFARMED and the competent Ethics Committee typically require Portuguese-language documentation for participant-facing materials and, in some cases, for the protocol synopsis. In Brazil, ANVISA submissions require Portuguese translations of the full protocol and supporting documents.
Quality and certification: what regulators expect
Regulatory authorities do not generally require notarised or sworn translation for clinical protocols. What they require is accuracy, traceability, and demonstrable quality. In practice, this means:
- A TEP process (Translation, Editing, Proofreading) carried out by translators with life sciences or pharmacology backgrounds
- Controlled terminology aligned with MedDRA, SNOMED CT, or EMA-published glossaries
- Version control — critical when protocols undergo successive amendments
- A translator's declaration or translation certificate attesting fidelity to the source document
ISO 17100:2015 certification is the recognised standard for translation process quality. For regulatory submissions, working with an ISO 17100-certified provider reduces the risk of rejection on linguistic or procedural grounds and provides an auditable quality trail.
Machine translation without specialist post-editing is not appropriate for clinical protocols. Errors in safety-critical terminology — adverse event classification, stopping rules, or contraindication language — carry regulatory and patient-safety consequences that cannot be corrected retroactively.
Managing protocol amendments and version control
A clinical trial protocol is a living document. A single trial may generate ten or more amendments over its lifecycle, and any amendment affecting sections previously submitted in translation must be translated and filed within the applicable regulatory deadline — in Portugal, typically within 30 days of sponsor approval.
Effective management of these updates requires a translation partner with maintained translation memories and shared glossaries, ensuring consistency across versions and reducing the cost and turnaround time for incremental updates. Sponsors and CROs that establish a standing arrangement with a specialist provider from the start of a trial are better positioned to meet amendment timelines without quality compromise.
Clinical trial protocol translation with M21Global
M21Global provides specialist medical and pharmaceutical translation services for regulatory submissions to INFARMED, the EMA, ANVISA, and other authorities across Portuguese-speaking and European markets. All projects follow the ISO 17100:2015 process (Bureau Veritas certified) and are reviewed by linguists with life sciences training. With over 300 million words translated across 20 years of operation, the team is equipped to handle high-complexity regulatory documentation on demanding schedules.
Request a quote for your clinical trial protocol translation — complete the form at m21global.com or contact the team directly to discuss project requirements and timelines.
